To this end, we are currently running a trial in ovarian cancer (NCT02452775) comparing OC-L vaccine alone with the addition of either Montanide (a water-in-oil emulsion possessing an immune stimulatory effect) or poly-ICLC alone (a TLR-3 agonist able to upregulate genes involved in innate immune pathways including IFN-α, IFN-β, IFN-γ upon administration in healthy volunteers [106]). The gene discussed is IFNG; the disease is ovarian cancer.